Leukotriene receptor antagonists and bronchial asthma;Leukotrienrezeptor-antagonisten und asthma bronchiale

Arzneimittel-Forschung/Drug Research

Volumn 48, Issue 3, 1998, Pages 205-211

  Jäger, Lothar ^a   Kroegel, Claus ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Antiasthmatic drugs; Leukotrienes, receptor antagonists

Indexed keywords

BAY 7195; CINALUKAST; IRALUKAST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; POBILUKAST; PRANLUKAST; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; DRUG USE; HUMAN; IMMUNITY; PATHOGENESIS; REVIEW;

ANIMALS; ANTI-ASTHMATIC AGENTS; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 0031943865     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Arm, J. P., Lee, T. H., Sulphidopeptide leukotrienes in asthma, Clin. Sci. 84, 501 (1993)
2. Calhoun, W. J, Lavins, B. J., Glass, M., Effect of Accolate (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation in patients with mild to moderate asthma, Allergy 50 (Suppl. 26), 117 (1995)
3. Calhoun, W. J., Williams, K. L., Simonson, S. D. et al., Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with mild to moderate asthma, Am. J. Respir. Crit. Care Med. 155, A662 (1997)
4. Carter, G. W., 5-Lipoxygenase inhibitors, in: Therapeutic immunology, K. F. Austen, S. J. Burakoff et al. (eds.), pp. 152-169, Blackwell Science, Cambridge (1996)
5. Chanarin, N., Johnston, S. L., Leukotrienes as a target in asthma therapy. Drugs 47, 12 (1994)
6. Cheng, J. B., Early efficacy data with a newer generation of LTD4 antagonists in anti-asthma trials: early promise for a single mediator antagonist, Pulmon. Pharmacol. 5, 77 (1992)
7. Crooke, S. T., Mattern, M., Sarau, H. M., The signal transduction system of the leukotriene D4 receptor, Trends Pharmacol. Sci. 10, 103 (1989)
8. Dahlen, S. E., Hedqvist, P., Hammarstroem, S. et al., Leukotrienes are potent constrictors of human bronchi, Nature 288, 484 (1980)
9. Feldberg, W., Kellaway, C. H., Liberation of histamine and formation of a lysolecithine-like substance by cobra venom, J. Physiol. 94, 187 (1938)
10. Findlay, S. R., Barden, J. M., Easley, C. B. et al., Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma, J. Allergy Clin. Immunol. 89, 1040 (1992)
11. Finnerty, J. P., Wood-Baker, R., Thomson, H. et al., Role of leukotrienes in exercise-induced asthma. Inhibitory effects of ICI 204,219, a potent leukotriene D4 receptor antagonist, Am. Rev. Respir. Dis. 145, 746 (1992)
12. Ford-Hutchinson, A. W., Leukotriene B4 in inflammation, Crit. Rev. Immunol. 10, 1 (1990)
13. Ford-Hutchinson, A. W., Rodger, I. W., Receptor site blockers, in: Therapeutic immunology, K. F. Austen, S. J. Burakoff et al. (eds.), pp. 132-151, Blackwell Science, Cambridge (USA) (1996)
14. Gaddy, J. N., Margolskee, D. J., Bush, R. K. et al., Bronchodilatation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma, Am. Rev. Respir. Dis. 146, 358 (1992)
15. Hiu, K. P., Barnes, N. C., Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist, Lancet 337, 1062 (1991)
16. Holgate, S. T., Bradding, P., Sampson, A. P., Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy, J. Allergy Clin. Immunol. 98, 1 (1996)
17. Howland, W. III., Segal, A., Glass, W. et al., 6-week therapy with oral leukotriene receptor antagonist ICI 204,219 in the treatment of asthma, J. Allergy Clin. Immunol. 93, 259 (1994)
18. Ishioka, S., Haruta, Y., Hozawa, S., Effect of a leukotriene receptor antagonist, ONO-1078, on serum eosinophil cationic protein (ECP) in patients with bronchial asthma, Eur. Respir. J. 9 (Suppl. 23), 273 (1996)
19. Israel, E., Cohn, J., Dube, L. et al., Chronic lipoxygenase (5-LO) inhibition by Zileuton significantly reduces the requirement for acute steroid treatment of asthma, Am. J. Respir. Crit. Care Med. 15, A678 (1995)
20. Jorg, A., Henderson, W. R., Murphy, R. C. et al., Leukotriene generation by eosinophils, J. Exp. Med. 155, 290 (1982)
21. Krell, R. D., Aharona, D., Buckner, C. K. et al., The preclinical pharmacology of ICI 204,219, a peptide leukotriene antagonist, Am. Rev. Respir. Dis. 141, 978 (1990)
22. Kroegel, C., Koenig, W., Jaeger, L., Erweiterte Therapie des Asthma bronchiale: Verwendung von 5-Lipoxygenase-Inhibitoren und Leukotrien-Rezeptorantagonisten, Dtsch. Ärzteblatt 94, A1802 (1997)
23. Laitinen, L. A., Laitinen, A., Haahtela, T. et al., Leukotriene E4 and granulocyte infiltration into asthmatic airways, Lancet 341, 989 (1993)
24. Leff, J. A., Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma. A randomized placebo-controlled trial, Am. J. Respir. Crit. Care Med. 155, A977 (1997)
25. Leff, J. A., Israel, E., Noonan, M. J. et al., Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability, Poster, ATS-Meeting, 21. 5. 1997, San Francisco
26. Lewis, R. A., Austen, K. F., Soberman, R. J., Leukotrienes and other products of the 5-lipoxygenase pathway, N. Engl. J. Med. 323, 645 (1990)
27. Maltby, N. H., Taylor, G. W., Ritter, J. M. et al., Leukotriene C4 elimination and metabolism in man, J. Allergy Clin. Immunol. 85, 3 (1990)
28. Manning, P. J., Watson, R. M., Margolskee, D. J. et al., Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 receptor antagonist, N. Engl. J. Med. 323, 1736 (1990)
29. Miller, D. K., Gillard, J. W., Vickers, P. J., Identification and isolation of membrane protein necessary for leukotriene production, Nature 343, 278 (1990)
30. Müller, M. J., Der Leukotriensignalweg - ein vielversprechender Ansatzpunkt für Inhibitoren in der Therapie entzündlicher Erkrankungen, Pharm. Z. 24, 264 (1995)
31. Peters, S. P., McGlashan, D. W., jr., Schulman, E. S. et al., Arachidonic acid metabolism in purified human lung mast cells, J. Immunol. 132, 1972 (1984)
32. Reiss, T. F., Altman, L. C., Chervinsky, P., Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma, J. Allergy Clin. Immunol. 98, 528 (1996)
33. Reiss, T. F., Chervinsky, P., Edwards, T. et al., Montelukast (MK-0476), a CYSLT1 receptor antagonist, improves the signs and symptoms of asthma after a 3-month treatment period, Eur. Respir. J. 9 (Suppl. 23), 273 (1996)
34. Reiss, T. F., Sorkness, C. A., Stricker, W. et al., Effect of montelukast (ML-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids, Thorax 52, 45 (1997)
35. Robuschi, M., Riva, E., Fucella, L. M. et al., Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (DK&F 104353), Am. Rev. Respir. Dis. 145, 1285 (1992)
36. Samuelsson, B., Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220, 568 (1983)
37. Smith, S. M., Christie, P. E., Hawksaworth, R. J. et al., Urinary leukotriene E4 levels following allergen and exercise challenge in bronchial asthma. Am. Rev. Respir. Dis. 144, 1411 (1991)
38. Spector, S. L., Antileukotrienes - 1997 and beyond, ACI International 9, 79 (1997)
39. Spector, S. L., Management of asthma with zafirlukast. Clinical experience and tolerability profile, Drugs 52 (Suppl. 6), 27 (1996)
40. Spector, S. L., Miller, C. J., Glass, M., 13-week dose-response study with Accolate (zafirlukast) in patients with mild to moderate asthma, Allergy 50, 117 (1995)
41. Spector, S. L., Smith, L. J., Glass, M., (and the Accolate Asthma Trialist group), The effects of six weeks therapy with oral doses of ICI 204,219 in asthmatics, Am. J. Respir. Crit. Care Med. 150, 618 (1994)
42. Taylor, I. K., O'Shaughnessy, K. M., Fuller, R. W. et al., Effect of the cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects, Lancet 337, 690 (1991)
43. Underwood, D. C., Osborn, R. R., Newsholme, S. J. et al., Persistent airway eosinophilia after leukotriene D4 administration in the guinea pig. Modulation by LTD4 receptor antagonist, panlukast or an interleukin-5 monoclonal antibody. Am. J. Respir. Crit. Care Med. 154, 850 (1996)